MGMT and glioblastoma: In addition, conjugating with radiotherapy, Cilengitide poses the potential for the utilization of this combined therapy for glioblastoma patients with O6-methylguanine DNA methyltransferase (MGMT) methylation in a completed 5-year analysis of the European Organization for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada (NCIC) trial (Robinson & Hodivala-Dilke, 2011).